FibroBiologics (FBLG) Stock Price, News & Analysis

Company Overview

FibroBiologics, Inc. (NASDAQ: FBLG) is a clinical-stage biotechnology company focused on developing novel therapeutics and imaging agents targeting fibroblast activation protein (FAP). The company’s proprietary platform is designed to modulate fibrotic and inflammatory processes that underlie a range of serious diseases, including oncology, cardiovascular disorders and degenerative conditions. By harnessing FAP’s unique expression profile, FibroBiologics aims to provide precision treatments that minimize off-target effects and improve patient outcomes.

FibroBiologics’ pipeline features both therapeutic and diagnostic candidates. Its lead therapeutic programs are being evaluated for the treatment of solid tumors and organ fibrosis, leveraging antibody–drug conjugates and small-molecule inhibitors that selectively bind to FAP-expressing cells. In parallel, the company is advancing radiolabeled imaging agents designed to visualize FAP distribution in vivo, potentially enabling earlier detection and more accurate monitoring of disease progression.

Founded in 2020 and headquartered in San Diego, California, FibroBiologics benefits from proximity to leading academic research centers and a vibrant biotech community. The company has established strategic partnerships with contract research organizations and academic institutions across North America and Europe to accelerate preclinical studies and scale up manufacturing. This global network supports FibroBiologics’ commitment to rigorous clinical development and regulatory compliance.

FibroBiologics is led by a management team with decades of combined experience in biotechnology, pharmaceutical development and regulatory affairs. The executive team has a track record of advancing novel therapies through clinical trials and securing global regulatory approvals. With its specialized focus on FAP-targeted approaches, FibroBiologics aims to address unmet medical needs in fibrosis and cancer, striving to bring transformative solutions to patients worldwide.

Key Stats

• Today's Range: $0.64 to $0.73
• 50-Day Range: $0.60 to $1.02
• 52-Week Range: $0.58 to $5.62
• Volume: 439,772 shs
• Average Volume: 309,306 shs
• Market Capitalization: $28.57 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $13.00
• Consensus Rating: Buy

FibroBiologics Stock Analysis - MarketRank™

FibroBiologics scored higher than 73% of companies evaluated by MarketBeat, and ranked 258th out of 937 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.6 / 5
• Analyst Rating: Buy

Consensus Rating

FibroBiologics has received a consensus rating of Buy. The company's average rating score is 3.20, and is based on 4 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

FibroBiologics has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for FibroBiologics are expected to grow in the coming year, from ($0.53) to ($0.38) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of FibroBiologics is -3.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of FibroBiologics is -3.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

FibroBiologics has a P/B Ratio of 9.00. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

2.74% of the float of FibroBiologics has been sold short.

Short Interest Ratio / Days to Cover

FibroBiologics has a short interest ratio ("days to cover") of 2.2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in FibroBiologics has recently decreased by 44.30%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

FibroBiologics does not currently pay a dividend.

Dividend Growth

FibroBiologics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

2.74% of the float of FibroBiologics has been sold short.

Short Interest Ratio / Days to Cover

FibroBiologics has a short interest ratio ("days to cover") of 2.2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in FibroBiologics has recently decreased by 44.30%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 3.0 / 5
• News Sentiment: 0.41

News Sentiment

FibroBiologics has a news sentiment score of 0.41. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.95 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 6 news articles for FibroBiologics this week, compared to 2 articles on an average week.

Search Interest

10 people have searched for FBLG on MarketBeat in the last 30 days. This is an increase of 25% compared to the previous 30 days.

MarketBeat Follows

5 people have added FibroBiologics to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: Acquiring Shares

Insider Buying vs. Insider Selling

In the past three months, FibroBiologics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $16,800.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

20.00% of the stock of FibroBiologics is held by insiders. A high percentage of insider ownership can be a sign of company health.

FBLG Stock Analysis - Frequently Asked Questions

How have FBLG shares performed this year?

FibroBiologics' stock was trading at $2.00 at the beginning of the year. Since then, FBLG stock has decreased by 64.0% and is now trading at $0.72.

How were FibroBiologics' earnings last quarter?

FibroBiologics Inc. (NASDAQ:FBLG) posted its earnings results on Tuesday, May, 13th. The company reported ($0.14) EPS for the quarter, missing analysts' consensus estimates of ($0.10) by $0.04.

When did FibroBiologics IPO?

FibroBiologics (FBLG) raised $144 million in an IPO on Wednesday, January 31st 2024. The company issued 4,806,226 shares at $30.00 per share.

How do I buy shares of FibroBiologics?

Shares of FBLG stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of FibroBiologics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that FibroBiologics investors own include Tesla (TSLA), NVIDIA (NVDA), Advanced Micro Devices (AMD), JPMorgan Chase & Co. (JPM), Meta Platforms (META), Visa (V) and Netflix (NFLX).

Company Calendar

• Last Earnings: 5/13/2025
• Today: 7/17/2025
• Next Earnings (Estimated): 8/06/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:FBLG
• Previous Symbol: NASDAQ:FBLG
• CIK: 1958777
• Web: www.fibrobiologics.com
• Phone: 281-671-5150
• Fax: N/A
• Employees: 10
• Year Founded: N/A

Price Target and Rating

• Average Price Target for FibroBiologics: $13.00
• High Price Target: $16.00
• Low Price Target: $12.00
• Potential Upside/Downside: +1,705.6%
• Consensus Rating: Buy
• Rating Score (0-4): 3.20
• Research Coverage: 5 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.21)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$11.16 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -1,022.04%
• Return on Assets: -117.56%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.14
• Quick Ratio: 1.14

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.08 per share
• Price / Book: 9.00

Miscellaneous

• Outstanding Shares: 39,680,000
• Free Float: 31,745,000
• Market Cap: $28.57 million
• Optionable: N/A
• Beta: -0.78